Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Pharm Stat. 2019 Nov 21;19(3):214–229. doi: 10.1002/pst.1983

Table 2:

The characteristics for optimal two-stage design with restricted follow-up x = 1, 2 under Weibull (WB), log-normal (LN), gamma (GM) and log-logistic (LG) distributions with nominal type I error 5%, power of 80%, accrual rate r = 10. Overall empirical type I error and power for the two-stage designs were estimated from 10,000 simulated trials.

Dist. Shape S 0 δ x t 1 c 1 c n 1 n α^ 1β^

WB 0.5 .3 .65 1 3.71 0.169 1.631 38 63 .039 .796
.3 .65 2 3.25 0.109 1.632 33 53 .038 .803
1 .3 .65 1 3.76 0.141 1.629 38 63 .039 .796
.3 .65 2 3.01 −0.042 1.635 31 46 .038 .813
2 .3 .65 1 3.74 0.068 1.629 38 63 .039 .797
.3 .65 2 2.88 −0.180 1.639 29 41 .037 .821

LN 0.5 .3 .65 1 3.84 0.110 1.628 39 63 .040 .801
.3 .65 2 2.93 −0.160 1.638 30 42 .038 .818
1 .3 .65 1 3.78 0.143 1.629 38 63 .040 .800
.3 .65 2 3.12 0.046 1.632 32 48 .038 .810
2 .3 .65 1 3.74 0.178 1.631 38 63 .040 .799
.3 .65 2 3.25 0.098 1.631 33 54 .038 .804

GM 0.5 .3 .65 1 3.71 0.151 1.631 38 63 .040 .801
.3 .65 2 3.13 0.055 1.633 32 50 .038 .808
1 .3 .65 1 3.76 0.141 1.629 38 63 .040 .800
.3 .65 2 3.01 −0.042 1.635 31 46 .037 .813
2 .3 .65 1 3.72 0.084 1.629 38 63 .040 .801
.3 .65 2 2.96 −0.109 1.637 30 43 .038 .815

LG 0.5 .3 .65 1 3.71 0.196 1.631 38 63 .040 .800
.3 .65 2 3.33 0.102 1.632 34 57 .039 .803
1 .3 .65 1 3.75 0.165 1.630 38 63 .040 .800
.3 .65 2 3.29 0.084 1.633 33 52 .038 .805
2 .3 .65 1 3.86 0.168 1.628 39 63 .040 .800
.3 .65 2 3.12 0.045 1.632 32 47 .037 .810

S0 is the survival probability at x0 under the null hypothesis; δ is the hazard ratio; x is the restricted follow-up period; t1 is the calendar time for the first-stage interim analysis; c1 and c are the boundaries for the first-stage and final analysis; n1 and n are the sample sizes for the first-stage and final analysis; Abbreviations: Dist.: distribution.